Oncopharmpod
MARIPOSA
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:10:20
- Mas informaciones
Informações:
Sinopsis
The MARIPOSA study suggests there may be a new preferred first line regimen (amivantamab + lazertinib) for metastatic EGFR-mutated NSCLC, as this regimen improved PFS compared to osimertinib.
